NEW YORK (GenomeWeb) — LifeMap Sciences announced on Thursday that it has signed an agreement to offer its TGex clinical genomics platform through Novogene's Tianjin, China-based clinical laboratory.
TGex is an NGS data analysis and interpretation platform, and was recently updated to include structural variations based on phenotypes. It is distributed in China by Shanghai Shanyi.
"Novogene Tianjin is a top tier provider of sequencing and bioinformatics solutions in China, and we are honored to have them select us to provide TGex as part of their bioinformatics platform," LifeMap CEO Guan Golan said in a statement. "The partnership with Novogene Tianjin will allow us to rapidly expand our offerings in the China market."
Specific terms of the deal were not disclosed.
Alameda, California-based LifeMap is a subsidiary of BioTime spinout AgeX Therapeutics.